Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved in the US and Japan. The European Commission approved the drug to treat ...

It's no secret dementia affects the brain of the patient, and tests the hearts of their loved ones. Through one woman's ...

The following is a summary of “Patient journey and decision processes for anti-amyloid therapy in Alzheimer’s disease,” ...

Women and individuals with a paternal history of Alzheimer disease have a stronger association between global β-amyloid and tau deposition.

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now caught ...

A study published in the American Journal of Human Genetics by researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's ...

New research suggests that calming the brain's immune cells might prevent or lessen the damaging inflammation seen in Alzheimer's disease.

With the recent rapid increase in life expectancy and the advancement of anesthesia technology, the demand for general ...